Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends

被引：176

作者：

Sun, Jack C. J. ^{[1
]}

Davidson, Michael J. ^{[2
]}

Lamy, Andre ^{[1
]}

Eikelboom, John W. ^{[3
]}

机构：

[1] McMaster Univ, Div Cardiac Surg, Hamilton, ON, Canada

[2] Harvard Univ, Sch Med, Div Cardiac Surg, Boston, MA USA

[3] McMaster Univ, Dept Med, Hamilton, ON, Canada

来源：

LANCET | 2009年 / 374卷 / 9689期

关键词：

PERCUTANEOUS TRANSCATHETER IMPLANTATION; ORAL ANTICOAGULANT-THERAPY; MOLECULAR-WEIGHT HEPARIN; CALCIFIC AORTIC-STENOSIS; SINGLE-CENTER EXPERIENCE; RATIO SELF-MANAGEMENT; HIGH-RISK PATIENTS; MECHANICAL VALVE; FOLLOW-UP; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

D O I：

10.1016/S0140-6736(09)60780-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over 4 million people worldwide have received a prosthetic heart valve, and an estimated 300000 valves are being implanted every year. Prosthetic heart valves improve quality of life and survival of patients with severe valvular heart disease, but the need for antithrombotic therapy to prevent thrombotic complications in valve recipients poses challenges for clinicians and patients. Here, we review antithrombotic therapies for patients with prosthetic heart valves and management of thromboembolic complications. Advances in antithrombotic therapy and valve technologies are likely to improve the management of patients with prosthetic heart valves in developed countries, but the most important unmet need and potential for benefit from these new therapies is in developing countries where a massive and rapidly increasing burden of valvular heart disease exists.

引用

页码：565 / 576

页数：12

共 132 条

[1] AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves [J].

Acar, J ;

Iung, B ;

Boissel, JP ;

Samama, MM ;

Michel, PL ;

Teppe, JP ;

Pony, JC ;

LeBreton, H ;

Thomas, D ;

Isnard, R ;

deGevigney, G ;

Viguier, E ;

Sfihi, A ;

Hanania, G ;

Ghannem, M ;

Mirode, A ;

Nemoz, C ;

Bossard, N ;

Rolland, C ;

Lion, L ;

Marsault, C ;

Ferroir, JP ;

Conard, J ;

Laborde, JP ;

Logeais, Y ;

Delahaye, JP ;

Guerin, F ;

Lainee, R ;

Lesbre, JP .

CIRCULATION, 1996, 94 (09) :2107-2112

[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[3]

*AM HEAT ASS, 2008, HEART DIS STROK STAT

[4] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation [J].

Anderson, Jeffrey L. ;

Horne, Benjamin D. ;

Stevens, Scott M. ;

Grove, Amanda S. ;

Barton, Stephanie ;

Nicholas, Zachery P. ;

Kahn, Samera F. S. ;

May, Heidi T. ;

Samuelson, Kent M. ;

Muhlestein, Joseph B. ;

Carlquist, John F. .

CIRCULATION, 2007, 116 (22) :2563-2570

[5] ACC/AHA 2006 practice guidelines for the management of patients with valvular heart disease: Executive summary [J].

不详 .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) :598-675

[6]

[Anonymous], NY TIMES

[7] Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation.: International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation [J].

Ansell, J ;

Jacobson, A ;

Levy, J ;

Völler, H ;

Hasenkam, JM .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 99 (01) :37-45

[8] The pharmacology and management of the vitamin K antagonists [J].

Ansell, J ;

Hirsh, J ;

Poller, L ;

Bussey, H ;

Jacobson, A ;

Hylek, E .

CHEST, 2004, 126 (03) :204S-233S

[9]

Antunes MJ, 2004, J HEART VALVE DIS, V13, pS7

[10]

ANTUNES MJ, 1988, J THORAC CARDIOV SUR, V95, P980

← 1 2 3 4 5 6 7 8 9 10 →